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Abstract
Background/Aim: Right sided colon cancer (RsCC) is proposed to be a distinct disease entity to left sided colon
cancer (LsCC). We seek to confirm primary tumour location as an independent prognostic factor in locoregional
colorectal cancer.
Methods: All patients with stage I – III primary adenocarcinoma of colon were identified from the New South
Wales (NSW) clinical cancer registry (2006–2013). Primary tumour location (RsCC vs LsCC) survival analyses were
conducted using the Kaplan-Meier method, and adjusted hazard ratios for 5-year all-cause mortality (OS) and
5-year cancer specific mortality (CSS) were obtained using Cox proportional hazards regression.
Results: We identified 9509 patients including 5051 patients with RsCC and 4458 with LsCC. Patients with RsCC
were more likely to be older, female, have a higher Charlson comorbidity index, and have worse tumour prognostic
factors. In univariate analysis of all stages combined, those patients with RsCC had a worse overall survival (OS, HR
1.20 95% CI 1.11–1.29, p < 0.0001), although this was not significant in the multivariate analysis (HR 0.96 95% CI 0.
89–1.04, p = 0.35). Stage I patients with RsCC had a trend to improved OS (multivariate HR 0.84 95% CI 0.69–1.01,
p = 0.07) and a significantly improved CSS (multivariate HR 0.51 95% CI 0.35–0.75, p = 0.0006). In stage II patients
with RsCC there was a significantly improved OS (multivariate HR 0.85 95% CI 0.75–0.98, p = 0.02) and CSS (multivariate HR
0.59 95% CI 0.45–0.78, p = 0.0002) compared to LsCC. In stage III patients, those with RsCC had a worse OS (multivariate HR
1.13 95% CI 1.01–1.26, p = 0.032) and a trend to worse CSS (multivariate HR 1.12 95% CI 0.94–1.33, p = 0.22).
Conclusions: Primary tumour location is an important prognostic factor in locoregional colon cancer with an effect that
varies by stage. RsCC is associated with lower all-cause mortality in stage II, and higher all-cause mortality in stage III.
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Background
Colorectal (CRC) is a common and lethal malignancy,
projected to account for 13% of all new cancer cases
diagnosed in Australia in 2015, and 10% of Australian
cancer deaths [1]. In recent years there has been increas-
ing interest in identifying the differences between right
sided and left sided colon cancer, and the potential for
using this clinical marker as a surrogate marker of
tumour biology, with the intent of improved personalisa-
tion of systemic treatments.
There is a growing body of evidence to suggest that
right sided colon cancers (RsCC) follow a different dis-
ease process compared to left sided tumours (LsCC).
The proximal and distal colons are physiologically separ-
ate, arising from distinct embryological origins, with dif-
ferences in tumour genetics, histology, presentation, and
clinical features [2–4]. Patients with RsCC are older,
more likely to be female, have more comorbidities, with
poorer tumour histopathological features [5–8].
Despite this, there is ongoing debate whether primary
tumour location is an independent prognostic factor in
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colon cancer. Most, but not all studies have found
poorer survival with RsCC [7–11]. A recent meta-
analysis found a statistically significant worse overall
survival in patients with RsCC, although there was sig-
nificant heterogeneity seen due the spectrum of included
study designs, disease stage, and limited information
about treatment received by patients [12]. Tumour stage
may play a role, with a large Surveillance, Epidemiology,
and End Results (SEER) program study showing worse
overall survival in Stage III RsCC patients, but not in
Stage I or II [7], although these finding have been re-
cently challenged by a propensity score matched analysis
of the SEER database, which showed a better prognosis
in RsCC patients [9].
This current study aims to use a prospectively col-
lected database of Australian patients to determine
whether primary tumour location is an independent
prognostic factor in locoregional colon cancer, and com-
pare our findings to the literature.
Methods
Patient cohort
The New South Wales (NSW) clinical cancer registry
contains demographic and clinical data for patients diag-
nosed or treated for cancer in NSW, covering approxi-
mately 30% of the Australian population. Data is
collected from pathological laboratories, hospitals and
oncology departments under mandatory notification of
new cancer cases irrespective of treatment.
We identified all patients with Stage I, II or III colo-
rectal cancer in NSW from Jan 2006 to 2013 (n = 9509)
as per third edition of the International Classification of
Diseases for Oncology (ICD-O-3) [13]. The registry also
contained adjuvant chemotherapy treatment details for a
more limited group of patients with stage II and III dis-
ease (n = 4102).
Mortality data, including cause of death, was obtained
with linkage to the NSW registry of Births, Deaths and
Marriages (BDM) by the Centre for Health Record Link-
age (CHeReL) [14]. The censor data for survival data
was 1st December 2014. Primary tumour location was
defined right sided (caecum to transverse colon) or left
sided (splenic flexure to rectosigmoid). Patients with rec-
tal cancer were excluded from analysis due to the differ-
ent treatment paradigm to colon cancer in locoregional
disease. No data was available for cause of death in 935
patients (10.1%) which were therefore excluded from the
cancer specific death analyses. Patients were deemed to
have died as a result of colon cancer only if the under-
lying cause of death, rather than an associated cause of
death, was coded as C18–20.
Comorbidity data was obtained by CHeReL linkage of
the clinical cancer registry data to the Admitted Patient
Data Collection (APDC). The APDC contains all admitted
patient services provided by New South Wales Public
Hospitals, Public Psychiatric Hospitals, Public Multi-
Purpose Services, Private Hospitals, and Private Day
Procedures Centres. Comorbidities of each patient were
quantified using the Charlson comorbidity index which
predicts mortality from a range of 22 comorbid conditions
[16]. ICD-10 codes were extracted from admissions prior
to diagnosis, then translated into a Charlson comorbidity
index (modified for cancer) using methods previously de-
scribed [15, 16].
All data linkage was performed by the Centre for
Health Record Linkage, with only de-identified informa-
tion provided to the researchers. The data sources used
for this study required ethical and data custodian ap-
proval to access, link (by an independent and approved
authority) and release for research. Approval for this
project was provided by the NSW Population & Health
Services Research Ethics Committee (approval HREC/
13/CIPHS/39).
Statistical analysis
Our primary outcome was all-cause 5-year overall sur-
vival (OS) stratified by stage, defined as death within
5 years of primary diagnosis of colon cancer on basis of
dates recorded in the cancer registry and BDM data-
bases. The secondary outcome was cancer specific 5 year
survival (CSS) stratified by stage, as per cause of death
encoded on BDM data. Median values for OS and CSS-
OS and corresponding 95% CI were calculated using
Kaplan-Meier methods. Unadjusted and multivariable
Cox proportional hazards regression analyses were used
to estimate the association between tumour location and
survival and to calculate corresponding hazard ratios
(HRs) and 95% confidence intervals (CIs). The following
variables were included in the multivariate model: age,
sex, Charlson Comorbidity Index, TNM stage, year of
diagnosis, grade, and adjuvant treatment (receipt and
type of adjuvant treatment performed in subset of pa-
tients only). All statistical analyses were performed using
SAS 9.2 software (SAS Institute, Inc., Cary, NC).
Results
Patient characteristics (n = 9509)
The characteristics of the NSW cohort is summarised in
Table 1. The mean follow up was 46 months (interquar-
tile range 27 to 71 months). At the end of 5 years of
follow up, 2686 (28.2%) patients had died, with 913 re-
ported deaths (34.0% of deaths) due to colon cancer.
22% of patients had stage I disease, 39% stage II, and
39% had Stage III. There were slightly more RsCC (53%)
than LsCC (47%). Patients with RsCC were older (61%
vs 47% older than 70 years), more likely to be female
(54% vs 42% female), had higher Charlson comorbidity
indices (CCI, 40% vs 34% CCI ≥ 1), and had worse
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prognostic features including higher TNM stage (79% vs
76% stage II/III), and higher grade tumour (23% vs 11%
poorly differentiated).
5 year all-cause mortality by primary tumour location
The observed 5 year OS for patients with RsCC was
66% (95% CI 65–67%) compared to 70% (95% CI 69–
72%) for LsCC. Unadjusted survival analysis demon-
strated a higher mortality with RsCC in all stages
combined (Fig. 1, univariate HR 1.20 95% CI 1.11–
1.29, p < 0.0001). When stratified by stage there was
significant difference in OS seen only in stage III,
with a higher mortality seen in RsCC (Fig. 1, HR 1.46
95% CI 1.31–1.63, p < 0.0001) (Fig. 1).
After adjusting for sex, age, comorbidities, stage,
grade, and year of diagnosis there was no significant dif-
ference in OS between RsCC and LsCC in patients from
all stages (multivariate HR 0.96 95% CI 0.89–1.04
p = 0.35) (Table 2). When the multivariate analysis was
stratified by stage, patients with RsCC had a trend to im-
proved survival in stage I (HR 0.84 95% CI 0.69–1.01,
p = 0.069), a statistically significant improved survival in
stage II (HR 0.85 95% CI 0.75–0.98, p = 0.02), but a
shorter survival in stage III (HR 1.13 95% CI 1.01–1.26,
p = 0.03) (see Table 3.)
Cancer specific survival (CSS) primary tumour location
The 5 year cancer specific survival (CSS) was similar for
RsCC (89%; 95% CI 88–90%) and LsCC (89%; 95% CI
Table 1 Patient characteristics (n = 9509)
Characteristic All Patients (%) Right sided tumour (%) Left sided tumour (%) P value
TNM stage I 2104 (22) 1055 (21) 1049 (24) <0.0001
II 3684 (39) 2059 (41) 1625 (36)
III 3721 (39) 1937 (38) 1784 (40)
T stage 1 1526 (16) 715 (14) 811 (18) <0.0001
2 1030 (11) 558 (11) 472 (11)
3 5075 (53) 2741 (54) 2334 (52)
4 1868 (20) 1031 (20) 837 (19)
N Stage 0 5788 (61) 3114 (62) 2674 (60) 0.06
1 3065 (32) 1576 (31) 1489 (33)
2 656 (7) 361 (7) 295 (7)
Grade Well differentiated 1244 (13) 635 (13) 609 (14) <0.0001
Mod. differentiated 6648 (70) 3278 (65) 3370 (76)
Poorly Differentiated 1617 (17) 1138 (23) 479 (11)
Age group ≤60 1925 (20) 798 (16) 1127 (25) <0.0001
61–70 2423 (25) 1189 (24) 1234 (28)
71–80 2814 (30) 1600 (32) 1214 (27)
>80 2347 (25) 1464 (29) 883 (20)
Sex Male 4913 (52) 2317 (46) 2596 (58) <0.0001
Female 4596 (48) 2734 (54) 1862 (42)
Charlson Comorbidity Index 0 5957 (63) 3027 (60) 2930 (66) <0.0001
1–2 5083 (22) 1172 (23) 911 (20)
3–4 1023 (11) 596 (12) 427 (10)
5 446 (5) 256 (5) 190 (4)
Adjuvant Chemotherapy None 1775 (19) 955 (46) 820 (40) 0.0002
Fluorouracil based 1098 (12) 553 (27) 545 (27)
Oxaliplatin doublet 1233 (13) 568 (27) 665 (33)
Unknowna 5403 2975 2428
Year Diagnosed 2006–2009 5018 (53) 2644 (52) 2374 (53) 0.38
2010–2013 4491 (47) 2407 (48) 2084 (47)
Totals 9509 5051 (53) 4458 (47)
aNot included in multivariate analysis in chemotherapy cohort
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87–90%). Unadjusted CSS analysis did not show a sig-
nificant difference between RsCC and LsCC in all stages
combined (Fig. 2, univariate HR 1.03 95% CI 0.91–1.18,
p = 0.64). When stratified by stage, there was a signifi-
cantly improved CSS seen with RsCC in stage I (HR 0.66
95% CI 0.45–0.95, p = 0.024) and stage II (HR 0.68 95%
CI 0.52–0.88 p = 0.0032), but a significantly poorer sur-
vival for stage III patients (HR 1.43 95% CI 1.21–1.66,
p < 0.0001) (Fig. 2, Table 3).
In the multivariate analysis, after adjusting for sex, age,
comorbidities, stage, grade, and year of diagnosis, patients
with RsCC had a statistically significant improved CSS in
all stages combined (HR 0.84, 95% CI 0.73–0.96, p = 0.011),
and for stage I (HR 0.51 95% CI 0.35–0.75, p = 0.0006) and
stage II (HR 0.59 95% CI 0.45–0.78, p = 0.0002) patients,
but a trend to worse survival in stage III (HR 1.12 95% CI
0.94–1.33, p = 0.22) (Table 3).
Effect of adjuvant chemotherapy
Adjuvant treatment details were available for 1631 (44%)
of patients with stage II and 2441 (66%) of patients with
stage III disease (4102 patients total). Most patients in
stage II disease did not receive adjuvant chemotherapy
(72%), with only a minority receiving fluorouracil mono-
therapy (24%) or an oxaliplatin doublet combination
(usually FOLFOX, 5%). In contrast, the majority of patients
with stage III disease received adjuvant chemotherapy
Fig. 1 5 year all-cause mortality by primary tumour location n = 9509 patients with 2686 deaths (Stage I = 2104 patients with 440 deaths, Stage
II = 3684 patients with 883 deaths, Stage III = 3721 patients with 1363 deaths)










Grade Well differentiated 1
Moderately differentiated 1.22 (1.06–1.39)
Poorly Differentiated 1.87 (1.60–2.17)











Year Diagnosed 2006–2009 1
2010–2013 0.98 (0.90–1.06)
HR Hazard Ratio, CI confidence interval
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(75%), with 28% treated with fluorouracil monotherapy,
and 47% with an oxaliplatin/ fluorouracil doublet. Higher
TNM-substage was associated with treatment with oxali-
platin doublet within both stage II (p < 0.0001) and III
(p = 0.0001). Consistent with current practice no patients
received adjuvant treatment with monoclonal antibodies.
Patients with RsCC were less likely to receive adjuvant
chemotherapy (p = 0.0002, Table 1) despite higher risk
tumour features. Adjuvant chemotherapy improved survival
in both RsCC (univariate OS HR 0.68; 95% CI 0.58–0.80)
and LsCC (univariate OS HR 0.48; 95% CI 0.40–0.58,
Additional file 1: Figure S1 and Additional file 2: Figure S2.
Inclusion of the adjuvant chemotherapy regimen into
the multivariate model did not alter the effect of primary
tumour location, although the results for RsCC in stage
II disease became non-significant (multivariate OS HR
0.86 95% CI 0.69–1.09 p = 0.19; multivariate CSS HR
0.67 95% CI 0.43–1.04, p = 0.07, Table 4). Patients with
RsCC in stage III colon cancer continued to have a sig-
nificantly inferior OS compared to LsCC even after ad-
justment for all above factors including receipt and type
of adjuvant chemotherapy (multivariate OS HR 1.29 95%
CI 1.11–1.50 p = 0.0012; multivariate CSS HR 1.16 95%
CI 0.92–1.47, p = 0.22, Table 4). When analyses were
Table 3 Univariate and multivariate Hazard Ratios for NSW cohort (n = 9509) stratified by stage. Statistically significant values in bold
Overall Survival HR (95% CI) Cancer Specific Survival HR (95% CI)
Univariate Multivariatea Univariate Multivariatea
All Patients Left Sided 1 1 1 1
Right Sided 1.20 (1.11–1.29) 0.96 (0.89–1.04) 1.03 (0.91–1.18) 0.84 (0.73–0.96)
Stage I (n = 2104) Left Sided 1 1 1 1
Right Sided 1.03 (0.91–1.18) 0.84 (0.69–1.01) 0.66 (0.45–0.95) 0.51 (0.35–0.75)
Stage II (n = 3684) Left Sided 1 1 1 1
Right Sided 1.002 (0.88–1.14) 0.85 (0.75–0.98) 0.68 (0.52–0.88) 0.59 (0.45–0.78)
Stage III (n = 3721) Left Sided 1 1 1 1
Right Sided 1.46 (1.31–1.63) 1.13 (1.01–1.26) 1.43 (1.21–1.69) 1.12 (0.94–1.33)
aFollowing variables were used in the multivariate analysis: age, sex, year diagnosed, Charlson Comorbidity Index, TNM stage, grade
Fig. 2 5 year cancer specific mortality by primary tumour location n = 9509 patients with 2686 deaths (Stage I = 2104 patients with 116 deaths,
Stage II = 3684 patients with 224 deaths, Stage III = 3721 patients with 573 deaths)
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restricted to only those stage III patients who received
adjuvant oxaliplatin doublet chemotherapy (n = 1233),
RsCC remained associated with a poorer OS (univariate
OS HR 1.8 95% CI 1.4–2.4, p < 0.0001).
Discussion
There are well established differences in patient
demographics, tumour factors and clinical presenta-
tion between RsCC and LsCC [7, 9, 10, 17, 18]. How-
ever it remains uncertain whether primary tumour
location is an independent prognostic factor in locor-
egional colon cancer.
The strongest evidence comes from a recent meta-
analysis of 66 studies including 1,437,846 patients which
showed LsCC is associated with a significantly reduced
risk of death compared to RsCC (HR 0.82; 95% CI 0.79–
0.84, P < 0.01) [12]. This study included all stages of
colon cancer and found that, based on meta-regression,
the effect of primary tumour location was independent
of stage, race, year of study, and quality of study.
It is important to consider the limitations of the above
meta-analysis. Firstly, there was significant heterogeneity
seen in the results (I2 = 93%), which is likely due to the
variety of included study designs, differing multivariate
covariates from source studies, and patient populations,
with the estimate derived from overall populations with
no stratification by stage.
Secondly, while most of the included studies con-
trolled for tumour factors (such as stage and grade), and
patient demographic factors (eg., age, sex), only three
studies included a comorbidity index in the multivariate
model [7, 17, 19], and only 21% (14 of 66 studies) in-
cluded performance status. RsCC is more likely to occur
in older patients who have more associated comorbidi-
ties [17], and the substantial imbalances in the baseline
characteristics between LsCC and RsCC patients in
these trials may be an unmeasured confounder which
explains the improved survival with LsCC. This issue
has been directly addressed by Warschkow et al. [9]
who, in order to minimise confounding, used propensity
score matching to analyse survival in RsCC versus LsCC
in 91,416 patients with stage I-III colon cancer from the
SEER database. These authors showed that RsCC had a
better OS (HR 0.89, p < 0.001) and CSS (HR 0.71,
p < 0.001) in stage I and II, but a similar prognosis in
stage III (OS HR 0.99, p = 0.49; CSS HR 1.04,
p = 0.129).
Our current study, using a large series of Australian
patients from a prospectively collected database, and
controlling for patient factors (including comorbidities),
tumour factors, and adjuvant chemotherapy, confirmed
previous studies showing that RsCCs are more likely to
have a more advanced stage (p < 0.0001) and grade
(p < 0.0001), and occur in older patients (p < 0.0001)
with more comorbidities (p < 0.0001). Despite higher
risk tumour features, patients with RsCC are less likely
to receive adjuvant chemotherapy (p < 0.0001) or oxali-
platin doublet chemotherapy (p = 0.0002).
In the survival analysis, patients with RsCC have a lower
all-cause mortality in stage II (HR 0.85, p = 0.02), but a
higher mortality in stage III (HR 1.13, p = 0.032). More-
over, patients with RsCC had an improved 5-year CSS in
Stage I (HR 0.51,p = 0.0006) and Stage II (HR 0.59,
p = 0.0002), and a trend to inferior CSS in Stage III.
As adjuvant chemotherapy has been shown to have a
larger benefit in RsCC than LsCC [20], we subsequently
undertook further multivariate analysis in a subset of pa-
tients with known adjuvant chemotherapy protocols to
validate our findings. Adjuvant chemotherapy improved
survival in both RsCC and LsCC. We found incorpor-
ation of adjuvant chemotherapy into the multivariate
Table 4 Multivariate model for overall survival for chemotherapy






HR (95% CI) HR (95% CI)
Sided Left 1 1
Right 0.86 (0.68–1.09) 1.29 (1.11–1.50)
Age ≤60 1 1
61–70 1.90 (1.20–2.99) 1.21 (0.94–1.54)
71–80 2.97 (1.92–4.58) 1.81 (1.43–2.30)






1.43 (1.08–1.90) 1.49 (1.26–1.75)
TNM stage IIIa 1 1
IIIb 2.20 (1.71–2.82)a 1.79 (1.33–2.43)
IIIc - 3.86 (2.84–5.24)
Sex Male 1 1
Female 0.85 (0.68–1.07) 0.94 (0.82–1.10)
CCI 0 1 1
1–2 1.42 (1.09–1.52) 1.15 (0.96–1.38)
3–4 1.60 (1.12–2.28) 1.20 (0.94–1.53)
5 2.31 (1.45–3.69) 1.83 (1.36–2.46)
Year Diagnosed 2006–2009 1 1










HR Hazard Ratio, CI confidence interval, CCI Charlson Comorbity index
aIIa vs IIb/IIc, bchemotherapy vs no chemotherapy
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model did not alter the effect of primary tumour loca-
tion. Although definitive conclusions were limited in
stage II as chemotherapy regimens where only available
in 44% of patients, there were similar hazard ratios
showing improved OS and CSS with RsCC (multivariate
HR 0.86 and 0.67 respectively), although statistically
non-significant in the chemotherapy cohort. In stage III,
where chemotherapy data was available for the major-
ity of patients (66%), the results of multivariate
analysis was very similar to overall cohort, with a sig-
nificantly higher all-cause mortality with RsCC (HR
1.29, p = 0.0012) and trend to higher cancer specific
mortality (HR 1.16, p = 0.21).
Our findings are consistent with the results of Wiess
et al. [7], a large multivariate retrospective analysis of
53,801 patients from the SEER database linked to
Medicare data, and controlled for comorbidities using
Hierarchical Condition Categories risk score. Similar to
our findings, in multivariate analysis, patients with RsCC
had a non-significant trend to lower mortality in stage I
(HR 0.95, p = 0.21), a lower mortality in stage II (HR
0.92, p < 0.0001), but a higher mortality in stage III (HR
1.12, p < 0.001), and a non-significant difference in mor-
tality overall (HR 1.01, p = 0.60). This stage dependant
effect, with an improved survival in RsCC in stage II,
but higher mortality in stage III, has been reported by
multiple other series [8–10, 18, 21].
The cause of the demonstrated inconsistent effect of
primary tumour location by stage is unclear. Our study,
and the quoted literature, are retrospective analyses of
large population databases, and are susceptible to the in-
herent bias of confounding associated with this study de-
sign. However an alternative explanation to consider is
the increasingly described differences in tumour biology
between RsCC and LsCC. RsCCs are more likely to have
adverse histological features (such as advanced T stage,
higher grade, or lymophvascular invasion) and mucinous
histology [2, 22–24]. Perhaps more importantly, there
are also marked differences in the molecular profile be-
tween these tumours [25]. RsCC has a higher rate of
BRAF mutations and high microsatellite instability
(MSI-H), both which have established prognostic
importance, with MSI-H tumours shown to have a
favourable prognosis, and BRAF a strong poor prognos-
tic marker in non-MSI-H but not in MSI-H tumours
[22, 23, 26, 27]. In addition even within MSI-H tumours
there are known differences in prognosis, with hereditary
MSI-H colon cancers shown to have a better survival
than sporadic cases [28]. It is important to note that
these biomarkers are not uniformly distributed by stage,
with MSI-H tumours associated with lower stage (21%
in stage II vs 14% stage III and 4% stage IV), and BRAF
mutant tumours more likely to occur at a higher stage
[22, 29, 30]. Furthermore, previous studies have shown a
differential effect of adjuvant chemotherapy in between
molecular subtypes. There is a reduced benefit with fluo-
rouracil based chemotherapy in MSI-H tumours, but
preserved efficacy of oxaliplatin in MSI-H stage III colon
cancer patients [31, 32]. Although our study demon-
strated a persistent effect of primary tumour location
even when OS analysis was restricted to those patients
who received adjuvant oxaliplatin doublet chemotherapy,
it is important to note that fewer patients with RsCC re-
ceived oxaliplatin as part of the adjuvant treatment.
Therefore, in the absence of both family history and
molecular profiles in these population series, it is rea-
sonable to hypothesise that some of the observed sur-
vival difference in stage II and III may be due to unequal
distribution of these biomarkers. However, emerging evi-
dence suggests that primary tumour location may be a
clinical surrogate for further, yet unidentified, predictive
biomarkers as highlighted by the recent data from the
FIRE3 and CALGB/SWOG 80405 trials, which suggests
a reduced benefit to anti-EGFR treatment in RsCC inde-
pendent of currently identified biomarkers [33]. A limi-
tation of our study is the lack of associated molecular
data which is a potential source of unmeasured con-
founding to the results.
Conclusion
This population based study provides further evidence
that primary tumour location is an important independ-
ent clinical prognostic factor in stage II and III colon
cancer with immediate implications for clinical practice
and trial design. This clinical biomarker is likely acting
as a surrogate for as yet unidentified molecular factors.
Further studies with associated tumour molecular pro-
files are required to clarify the underlying biological dif-
ferences between RsCC and LsCC.
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